Considering the effect of CT on hemorrhagic risk in glioma patients, a possible negative influence has been attributed to bevacizumab, a recombinant humanized monoclonal antibody directed against VEGF and used for the treatment of recurrent and progressive glioblastoma multiforme (1, 153, 154) Despite its efficacy in increasing progression-free survival and in improving symptoms, early clinical studies have shown a possible increased risk of hemorrhage within and adjacent to the tumor, and a history of ICH is a relative contraindication to bevacizumab therapy (155, 156). The gene discussed is VEGFA; the disease is neoplasm.